Eli Lilly and Company (NYSE:LLY) jumped 0.05 points or 0.07% on strong buying and was last priced at $74 per share. The shares saw huge fund flow intraday; a massive $39.54 million made their way in through the upticks but an even bigger $42.84 million made their way out through downticks. As per the last observation, the net money flow stood at $(-3.3) million and the up/down ratio was found to be 0.92. The shares have seen a weekly value change of -1.49% .A block trade was recorded in the company shares with a net money flow of $(-0.13) million. The composite value of the funds in upticks was $4.02 million and the total value of funds in downticks was $4.15. As can be seen from the data, the block transaction had the up/down ratio of 0.97.
Currently the company Insiders own 0.2% of Eli Lilly and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.61% . Institutional Investors own 76.21% of Eli Lilly and Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.63%. On the companys insider trading activities, Tai Jackson P, director of Lilly Eli & Co had purchased 1,080 shares on May 12, 2016 in a transaction. The price per share was $75.75 and the total amount of the disclosed transaction was $81,810.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Eli Lilly and Company (NYSE:LLY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.09 points or 0.12% at $73.86 with 3,767,039 shares getting traded. Post opening the session at $74.08, the shares hit an intraday low of $73.67 and an intraday high of $74.97 and the price was in this range throughout the day. The company has a market cap of $81,529 million and the number of outstanding shares have been calculated to be 1,103,837,000 shares. The 52-week high of Eli Lilly and Company (NYSE:LLY) is $92.85 and the 52-week low is $67.88.
Many analysts have stated their opinion on the company shares. In a research note released to the investors, Leerink Swann maintains its rating on Eli Lilly and Company (NYSE:LLY).The analysts at the brokerage house have a current rating of Outperform on the shares. In a recent information released to the investors, Leerink Swann raises the new price target from $96 per share to $101 per share. The rating by the firm was issued on May 2, 2016.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.